Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 2/20 | 0.41 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5815037 | 0.91 | MAOB (0.44) | APPCYP1A1CYP1B1MAOBLSS | |
| SCHEMBL4744399 | 0.85 | MIF (0.48) | MAPK14GCGRLSSMEN1ALOX15 | |
| SCHEMBL22871555 | 0.85 | MAPK13 (0.44) | APPCYP1A1CYP1B1MAOBMAPK14 | |
| SCHEMBL5043116 | 0.85 | LSS (0.54) | APPCYP1A1CYP1B1MAOBTP53 | |
| SCHEMBL6281250 | 0.85 | XDH (0.49) | APPCYP1A1CYP1B1MAOBTP53 | |
| SCHEMBL8341333 | 0.84 | PIN1 (0.51) | MAOBTP53NPC1RAB9AMEN1 | |
| SCHEMBL6984133 | 0.83 | MAPT (0.44) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| Hydrochloric Acid SCHEMBL6981985 | 0.82 | MAPT (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL17154291 | 0.80 | APP (0.45) | APPTP53MAPK14GCGRNPC1 | |
| SCHEMBL6285585 | 0.79 | ALDH1A1 (0.40) | APPMAOBLSSNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10888545-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3192795-B1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3192795-B1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2020-12-02 | — | — | EP | disclosed |
| US-10464930-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464930-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-11-05 | — | — | US | disclosed |
| US-10160752-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2018-08-02 | — | — | US | disclosed |
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2018-08-02 | — | — | US | disclosed |
| US-9895348-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-20 | — | — | US | disclosed |
| US-9895348-B2 | Compositions and methods for treating estrogen-related medical disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-20 | — | — | US | disclosed |
| WO-2014066692-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-01 | — | — | WO | disclosed |
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464930-B2 | Compositions and methods for treating estrogen-related medical disorders | HSD17B11, CYP19A1, ESR1 | APP 3557/4885CYP1A1 192/4885CYP1B1 245/4885 |
| US-10160752-B2 | Compositions and methods for treating estrogen-related medical disorders | HSD17B11, CYP19A1, ESR1 | APP 3557/4885CYP1A1 192/4885CYP1B1 245/4885 |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | APP 4040/4885CYP1A1 272/4885CYP1B1 185/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | APP 4089/4885CYP1A1 153/4885CYP1B1 74/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | APP 4089/4885CYP1A1 153/4885CYP1B1 74/4885 |
| US-10888545-B2 | Compositions and methods for treating estrogen-related medical disorders | HSD17B11, SHBG, ESRRB | APP 4504/4885CYP1A1 686/4885CYP1B1 586/4885 |
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | APP 4504/4885CYP1A1 686/4885CYP1B1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.